Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms

Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8.

Anna B Halpern^{1

2}, Megan Othus³, Emily M Huebner¹, Bart L Scott^{1

4}, Paul C Hendrie^{2

5}, Mary-Elizabeth M Percival^{1

2}, Pamela S Becker^{1

2}, Heather A Smith⁵, Vivian G Oehler^{1

2}, Johnnie J Orozco^{1

2}, Ryan D Cassaday^{1

2}, Kelda M Gardner², Tara L Chen⁶, Sarah A Buckley⁷, Kaysey F Orlowski¹, Asma Anwar⁷, Elihu H Estey^{1

2}, Roland B Walter^{8

2

9}

¹ Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
² Department of Medicine, Division of Hematology, University of Washington.
³ Public Health Sciences Division, Fred Hutchinson Cancer Research Center.
⁴ Department of Medicine, Division of Medical Oncology, University of Washington.
⁵ Seattle Cancer Care Alliance.
⁶ Deparment of Pharmacy Services, University of Washington.
⁷ Hematology/Oncology Fellowship Program, University of Washington/Fred Hutchinson Cancer Research Center.
⁸ Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington rwalter@fredhutch.org.
⁹ Department of Epidemiology, University of Washington, Seattle, WA, USA.

No abstract available

Publication types